Abstract:RNA viruses continue to remain a clear and present threat for potential pandemics due to their rapid evolution. To mitigate their impact, we urgently require antiviral agents that can inhibit multiple families of disease-causing viruses, such as arthropod-borne and respiratory pathogens. Potentiating host antiviral pathways can prevent or limit viral infections before escalating into a major outbreak. Therefore, it is critical to identify broad-spectrum antiviral agents. We have tested a small library of innate immune agonists targeting pathogen recognition receptors, including TLRs, STING, NOD, Dectin and cytosolic DNA or RNA sensors. We observed that TLR3, STING, TLR8 and Dectin-1 ligands inhibited arboviruses, Chikungunya virus (CHIKV), West Nile virus (WNV) and Zika virus, to varying degrees. Cyclic dinucleotide (CDN) STING agonists, such as cAIMP, diABZI, and 2',3'-cGAMP, and Dectin-1 agonist scleroglucan, demonstrated the most potent, broad-spectrum antiviral function. Comparative transcriptome analysis revealed that CHIKV-infected cells had larger number of differentially expressed genes than of WNV and ZIKV. Furthermore, gene expression analysis showed that cAIMP treatment rescued cells from CHIKV-induced dysregulation of cell repair, immune, and metabolic pathways. In addition, cAIMP provided protection against CHIKV in a CHIKV-arthritis mouse model. Cardioprotective effects of synthetic STING ligands against CHIKV, WNV, SARS-CoV-2 and enterovirus D68 (EV-D68) infections were demonstrated using human cardiomyocytes. Interestingly, the direct-acting antiviral drug remdesivir, a nucleoside analogue, was not effective against CHIKV and WNV, but exhibited potent antiviral effects against SARS-CoV-2, RSV (respiratory syncytial virus), and EV-D68. Our study identifies broad-spectrum antivirals effective against multiple families of pandemic potential RNA viruses, which can be rapidly deployed to prevent or mitigate future pandemics.

[Surgical treatment of sternal tumors: resection of the tumors and reconstruction of the chest wall defects].

Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections

Exploiting the Achilles’ Heel of Viral RNA Processing to Develop Novel Antivirals

Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses

Viral RNA capping: Mechanisms and antiviral therapy

Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics

Antiviral RNAi therapy: emerging approaches for hitting a moving target

Engineered External Guide Sequences Effectively Block Viral Gene Expression and Replication in Cultured Cells

Host Cell Targets for Unconventional Antivirals against RNA Viruses

Bioactive dressings: old ideas, new technology.

Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonoses

Molecular Engineering of Virus Tropism

Using a combined protection motivation theory and health action process approach intervention to promote exercise during pregnancy

Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis

Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease.

Directed evolution of an orthogonal transcription engine for programmable gene expression in eukaryotes

Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses

RNA viruses as virotherapy agents

Reactive Oxygen Intermediates Activate NF-KB in a Tyrosine Kinase-Dependent Mechanism and in Combination With Vanadate Activate the ~ 5 6 ’ ‘ ~ and ~ 5 9 ‘ ~ ” Tyrosine Kinases in Human Lymphocytes

Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential